New Frontiers in the Treatment and Management of Alzheimer's Disease (AD):
What Managed Care Needs to Know about New and Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Alzheimer's Disease (AD)

These are archives of live webinars held between November 12 to November 18, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These activities are valid from December 15, 2020 to December 1, 2022


This series is supported by an educational grant from Biogen


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Alzheimer’s disease care costs $172 billion annually in the US alone. Fortunately for patients with Alzheimer's disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been submitted for regulatory review. This program will provide strategies to overcome challenges in the optimal treatment and management of Alzheimer’s disease and highlight the role of managed care professionals in making informed decisions on these new and emerging therapies that will improve quality of life, significantly reduce clinical decline, and minimize costs throughout the healthcare system.


Benefit Design and Coordinated Care in Alzheimer’s Disease (AD): What Managed Care Needs to Know about Emerging Therapies and Reducing Clinical Decline

  1. Analyze the economic burden of Alzheimer’s disease (AD) and the impact of suboptimal management on outcomes
  2. Review the latest clinical data on novel and emerging therapies, including monoclonal antibodies, in the management of patients with alzheimer"s disease (AD)
  3. Characterize the role of managed care professionals in supporting appropriate utilization and administration of emerging therapies for AD
  4. Develop formulary positioning and benefit design strategies for emerging AD therapies that encourage appropriate utilization while facilitating patient access and adherence
  5. Assess the managed care considerations of new and emerging therapies, including monoclonal antibodies, by exploring where these agents fit in the AD management paradigm
  6. Identify practices that managed care professionals can use both now and in the future to help improve outcomes, reduce clinical decline and ensure appropriate and timely access to emerging therapies in AD
       Physician, Nursing and CMCN credits valid to December 1, 2022

Improving Patient Adherence and Quality of Life in Alzheimer’s Disease (AD): Optimizing Adverse Event Management and Imaging for Emerging Therapies

  1. Examine challenges to patient adherence, administration and quality of life in the management of alzheimer’s disease (AD)
  2. Discuss strategies to implement emerging therapies, including monoclonal antibodies, into the treatment paradigm, especially as it relates to patient adherence and quality of life
  3. Evaluate adverse events associated with emerging therapies and strategies to mitigate and manage these predictable toxicities that have been reported in clinical trials
  4. Explore the role of neuroimaging in the diagnosis of AD, confirmation of beta-amyloid deposition, monitoring of disease progression, and monitoring of ARIA associated with investigative anti-β amyloid monoclonal antibody therapies for maintaining patient adherence and QoL
  5. Identify practices that managed care professionals can use both now and in the future to help improve outcomes, reduce clinical decline and ensure appropriate and timely access to emerging therapies in AD
       Physician, Nursing and CMCN credits valid to December 1, 2022

A Deeper Look into Emerging Therapies in the Management of Alzheimer’s Disease (AD): What Does Recent Clinical Trial Data Have to Say?

  1. Characterize the clinical and economic burden of Alzheimer’s disease (AD) in terms of incidence and prevalence as well as direct and indirect costs
  2. Describe various diagnostic tools for AD and evaluate their respective benefits and disadvantages for standardized use among network providers
  3. Explore recent clinical trial data on the efficacy, safety and mechanisms of action of new and emerging therapies in the management of AD
  4. Analyze the emerging role of anti-beta-amyloid (Aß) monoclonal antibodies in the management of AD for reduction in clinical decline
  5. Appraise the clinical benefits of novel therapeutics addressing neuropsychological symptoms and disease modifying agents in the management of AD
       Physician, Nursing and CMCN credits valid to December 1, 2022